Global Information
회사소개 | 문의 | 비교리스트

전이성 포도막 흑색종 : 파이프라인 리뷰

Metastatic Uveal Melanoma - Pipeline Review, H2 2016

리서치사 Global Markets Direct
발행일 2016년 12월 상품 코드 305183
페이지 정보 영문 56 Pages
가격
US $ 2,000 ₩ 2,417,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,834,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,251,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


전이성 포도막 흑색종 : 파이프라인 리뷰 Metastatic Uveal Melanoma - Pipeline Review, H2 2016
발행일 : 2016년 12월 페이지 정보 : 영문 56 Pages

전이성 포도막 흑색종이란 안구(포도막)로부터 인체의 다른 부위로 전이하는 암을 가리킵니다. 간으로의 전이가 가장 많으며, 폐·뼈·피부 직하(피하)로의 전이도 많이 볼 수 있습니다. 주요 증상에는 황달 및 피부 가려움·발진, 간 내부 효소의 이상 증가, 복통, 식욕부진, 구역·구토 등을 들 수 있습니다. 주요 치료법에는 외과 수술 및 화학요법, 방사선 치료 등이 있습니다.

세계 각국의 전이성 포도막 흑색종 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발·출시의 최신 동향, 임상시험 단계별 제품 리스트, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 정리하여 전해드립니다.

1. 목차

2. 서론

  • 분석 범위

3. 전이성 포도막 흑색종 개요

4. 치료제 개발

  • 전이성 포도막 흑색종용 파이프라인 제품 : 개요
  • 전이성 포도막 흑색종용 파이프라인 제품 : 비교 분석

5. 각 기업에서 개발중인 전이성 포도막 흑색종 치료제

6. 파이프라인 제품 개요

  • 후기 단계 제품
  • 임상시험 단계 제품

7. 전이성 포도막 흑색종 치료제 : 개발중인 제품(기업별)

8. 전이성 포도막 흑색종 치료제 개발에 종사하고 있는 기업

  • AstraZeneca PLC
  • Eli Lilly and Company
  • Novartis AG
  • Pfizer Inc.
  • Spectrum Pharmaceuticals, Inc.

9. 전이성 포도막 흑색종 : 치료제 평가

  • 단일 치료제의 경우
  • 표적별
  • 작용기서별
  • 투여 방법별
  • 분자 종류별

10. 약제 개요

  • selumetinib sulfate
    • 제품 개요
    • 기능 메커니즘
    • 연구개발(R&D) 진전 상황
  • sunitinib malate
  • vincristine sulfate liposomal
  • LY-2801653
  • sotrastaurin acetate
  • MEK-162

11. 전이성 포도막 흑색종 치료제 : 파이프라인 제품의 최신 동향

12. 전이성 포도막 흑색종 치료제 : 개발 휴지 상태 제품

13. 전이성 포도막 흑색종 관련 제품 개발의 마일스톤

  • 주목할 만한 최신 동향·프레스 릴리스(총 2건)

14. 부록

15. 도표

KSA 14.07.03

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metastatic Uveal Melanoma - Pipeline Review, H2 2016, provides an overview of the Metastatic Uveal Melanoma (Oncology) pipeline landscape.

Metastatic uveal melanoma is a cancer that has spread from the eye (uveal) to other parts of the body. The most common site of metastasis for uveal melanoma is the liver. Other common sites of metastasis include the lung, bones and just beneath the skin (subcutaneous). Symptoms include jaundice, itchy skin or rash, abnormally high enzymes in the liver, abdominal pain, appetite loss, nausea, and vomiting. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Metastatic Uveal Melanoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Metastatic Uveal Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Metastatic Uveal Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Metastatic Uveal Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and IND/CTA Filed stages are 3, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Metastatic Uveal Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Metastatic Uveal Melanoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Metastatic Uveal Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Metastatic Uveal Melanoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Metastatic Uveal Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Metastatic Uveal Melanoma (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Metastatic Uveal Melanoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Metastatic Uveal Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Metastatic Uveal Melanoma Overview
  • Therapeutics Development
    • Pipeline Products for Metastatic Uveal Melanoma - Overview
    • Pipeline Products for Metastatic Uveal Melanoma - Comparative Analysis
  • Metastatic Uveal Melanoma - Therapeutics under Development by Companies
  • Metastatic Uveal Melanoma - Therapeutics under Investigation by Universities/Institutes
  • Metastatic Uveal Melanoma - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Metastatic Uveal Melanoma - Products under Development by Companies
  • Metastatic Uveal Melanoma - Products under Investigation by Universities/Institutes
  • Metastatic Uveal Melanoma - Companies Involved in Therapeutics Development
    • Bellicum Pharmaceuticals Inc
    • Celldex Therapeutics Inc
    • Eli Lilly and Company
    • Novartis AG
    • Spectrum Pharmaceuticals Inc
  • Metastatic Uveal Melanoma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • alpelisib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BPX-701 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • emibetuzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • glembatumumab vedotin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KCN-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LXS-196 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • merestinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sotrastaurin acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vincristine sulfate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Metastatic Uveal Melanoma - Dormant Projects
  • Metastatic Uveal Melanoma - Discontinued Products
  • Metastatic Uveal Melanoma - Product Development Milestones
    • Featured News & Press Releases
      • Apr 18, 2016: Celldex Therapeutics Presents data on Glembatumumab Vedotin at AACR 2016
      • Jan 11, 2016: Bellicum Pharmaceuticals Announces Submission of BPX-701 Clinical Trial Protocols for Review by the NIH RAC
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Metastatic Uveal Melanoma, H2 2016
  • Number of Products under Development for Metastatic Uveal Melanoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Metastatic Uveal Melanoma - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016
  • Metastatic Uveal Melanoma - Pipeline by Celldex Therapeutics Inc, H2 2016
  • Metastatic Uveal Melanoma - Pipeline by Eli Lilly and Company, H2 2016
  • Metastatic Uveal Melanoma - Pipeline by Novartis AG, H2 2016
  • Metastatic Uveal Melanoma - Pipeline by Spectrum Pharmaceuticals Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Metastatic Uveal Melanoma - Dormant Projects, H2 2016
  • Metastatic Uveal Melanoma - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Metastatic Uveal Melanoma, H2 2016
  • Number of Products under Development for Metastatic Uveal Melanoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top
전화 문의
F A Q